Direct compression of the 29-residue 9-37 peptide sequence into an immediate-release oral tablet is developed as a low-moisture solid dosage form only after dynamic vapour sorption data confirm that the API does not gain more than 2.0 % weight at 60 % RH within 24 h. The processing suite is held at 25 ± 3 °C and ≤ 30 % RH, and the API is pre-sieved through a 150 µm stainless-steel mesh to break loosely bound agglomerates. A starting powder blend contains 5–15 wt% peptide, 70–80 wt% spray-dried mannitol with a D50 of 75–125 µm, 3–6 wt% crospovidone as a non-ionic disintegrant, 0.5–1.0 wt% magnesium stearate, and 0.5–2.0 wt% colloidal silicon dioxide as a glidant. Lactose monohydrate is excluded from the primary formulation matrix because the reducing sugar can form Schiff-base adducts with free amino groups on the peptide under moisture stress, leading to yellowing and assay loss; mannitol is preferred for its non-reducing, low-hygroscopic character. The API is first geometrically pre-blended with mannitol in a 1:1 ratio in a Turbula mixer at 22 rpm for 10 min, followed by addition of the remaining filler and disintegrant and blending in a bin blender at 10–15 rpm for 15–20 min. Magnesium stearate is added through a 500 µm screen at the final lubrication stage and blended for 3–5 min to avoid excessive shear that can delaminate peptide aggregates and reduce tensile strength. Tableting is performed on a rotary press with 8–12 kN main compression force and 2–4 kN pre-compression, with a target tablet hardness of 4–7 kp, friability below 1.0 % per USP 1216, and disintegration time below 15 min in 37 ± 2 °C water per USP 701. Blend uniformity and content uniformity are verified per USP 905 or Ph. Eur. 2.9.40, with acceptance values not exceeding L1 = 15. Film coating, when required for light protection or taste masking, is applied as a low-viscosity HPMC E5 or PVA-based coat at 3–5 % weight gain in a pan coater with inlet air temperature 60–70 °C and product temperature 38–42 °C. The terminal dosage form is an immediate-release film-coated tablet with a target mass of 80–250 mg, intended for oral administration, with moisture content by Karl Fischer USP 921 Method Ia controlled to < 2.0 % in bulk packaging with desiccant.

The direct compression route carries a processing boundary: if the peptide powder has a D90 above 800 µm or a bulk density below 0.25 g/mL, flow segregation becomes probable and the batch should be switched to dry granulation using roller compaction with roll gap 0.5–1.5 mm and roll force 5–15 kN/cm. The roller-compacted ribbons are milled through a 0.8 mm screen and re-lubricated; this route reduces segregation but may produce fines below 75 µm that raise dissolution variability. Published data for this specific peptide sequence in direct compression is limited; therefore, the initial formulation space is bracketed using a three-factor design where peptide load, crospovidone level, and magnesium stearate mixing time are varied to map content uniformity, disintegration, and dissolution responses. For batches that fail disintegration due to hydrophobic lubrication, reducing magnesium stearate from 1.0 % to 0.5 % and increasing crospovidone from 3 % to 5 % is the first corrective step. All experimental data are generated under ICH Q1A(R2) and ICH Q3B impurity thresholds, and cleaning validation follows 21 CFR 211.67 because the API is a peptide with possible sensitization risk on shared manufacturing lines.

What Limits Hard Capsule Fill Uniformity for Low-Dose Peptide Blends?

For low-dose hard capsule filling of the 9-37 peptide, development begins with the selection of a low-aldehyde capsule shell, because gelatin shells can contain formaldehyde and glutaraldehyde-derived cross-linking agents that form an insoluble pellicle on the capsule surface and slow dissolution at the 45 min time point in USP 711 Apparatus II. Hypromellose capsules, size 3 or 4, are preferred when the API dose is below 10 mg and the fill mass is 120–180 mg. A direct filling powder blend contains 2–8 wt% peptide, 78–90 wt% microcrystalline cellulose PH-102 or silicified microcrystalline cellulose, 3–6 wt% crospovidone, 0.5–1.5 wt% sodium stearyl fumarate, and 0.5–1.5 wt% fumed silica. Sodium stearyl fumarate is used in place of magnesium stearate where the peptide has a net positive charge at gastric pH, because stearate films can create a delayed-release artifact in dissolution testing if the mixing time exceeds 5 min. The blend is loaded into a dosator or tamping-pin capsule filler under ≤ 35 % RH; target fill weight is controlled to ± 5 % RSD by adjusting the dosing disc thickness between 2.0 mm and 3.5 mm and by maintaining a powder bed depth of 5–10 mm in the hopper. Powder flow is pre-qualified by measuring Carr index 15–25 % and Hausner ratio 1.15–1.25; blends outside this range are dry-granulated or the MCC grade is changed to PH-200 with larger D50. Dissolution testing uses USP 711 Apparatus II at 50 rpm with a sinker, and if gelatin cross-linking is suspected, the medium may include pepsin at 0.1 % w/v per the USP 711 monograph note for gelatin capsules. Content uniformity follows USP 905 or Ph. Eur. 2.9.40, and the acceptance value should be tightened to L2 = 15 for early clinical batches. Terminal product is a hypromellose hard capsule, protected from moisture by aluminium-aluminium blister packs with desiccant, and is intended for oral administration when dose titration or blinding of a comparator requires encapsulation of milled tablet cores or multiparticulates.

Capsule-specific incompatibility arises from shell moisture exchange: if the fill has a water activity above 0.55 at 25 °C, the HPMC shell becomes pliable and may deform on the filling pins, producing split caps; conversely, fill below 0.25 water activity can draw residual moisture from the shell and embrittle the capsule over storage. The blend should therefore be equilibrated to 30–40 % RH before filling, and the filled capsules should be sealed with a low-viscosity HPMC or ethylcellulose banding solution at 3–8 mg band weight to reduce oxygen ingress. For the 9-37 peptide, oxidation-sensitive methionine or cysteine residues are protected by purging the hopper with nitrogen and by adding 0.1–0.5 wt% of a non-volatile antioxidant such as butylated hydroxytoluene or alpha-tocopherol only if oxidative degradation is demonstrated by forced oxidation with 0.3 % hydrogen peroxide. The addition of antioxidants is not default; it is required only when peroxide spiking produces a degradation product above 0.5 % by peak area in a validated HPLC method. Operational boundary: electrostatic charging of the powder blend in low-humidity environments can cause powder adhesion to the capsule shell inner wall; anti-static additives such as 0.25–0.5 % sodium lauryl sulfate are added only if dissolution remains unaffected in USP 711 at the first sampling point.

Before wet granulation is selected for the 9-37 peptide sequence, fluid-bed dry granulation is evaluated because the peptide contains N-terminal and side-chain amine functionalities that can form Maillard adducts with reducing sugars and can undergo hydrolysis in aqueous binder systems above 40 °C. For a granule-filled sachet or stick pack, a top-spray fluid-bed process on a Glatt GPCG-3 or equivalent is configured with a 0.8–1.0 mm nozzle, atomization air 0.8–1.5 bar, inlet air temperature 45–55 °C, product temperature 28–34 °C, and spray rate 5–12 g/min/kg. The binder solution is povidone K30 at 3–5 % w/w in a water-ethanol mixture not exceeding 30 % v/v water, adjusted so that the peptide remains below its aqueous solubility limit and does not precipitate on the nozzle. Starting granule composition is 5–12 wt% peptide, 60–75 wt% mannitol, 10–20 wt% microcrystalline cellulose, 2–5 wt% povidone K30, 1–2 wt% talc, and 0.25–0.5 wt% sodium citrate dihydrate as a pH-buffering salt if acid-catalyzed hydrolysis is observed. Granules are dried in the fluid bed until the product temperature reaches 40 °C for 10 min, then sieved through 500 µm and retained on 150 µm; the yield fraction outside this cut is milled and re-passed only once to avoid excessive fines. Particle size distribution is measured by USP 786 analytical sieving, with d10 ≥ 75 µm, d50 = 180–400 µm, and d90 ≤ 800 µm. Loss on drying is controlled to < 2.0 % by Karl Fischer USP 921 Method Ia, and the granules are filled into stick packs at 150–250 mg fill weight under ≤ 30 % RH using vertical form-fill-seal equipment with a nitrogen flush to displace headspace oxygen. Terminal product is an oral granule for reconstitution or direct administration; for suspension, 15–20 mL of water at 20–25 °C is added, and the dispersion should pass through a 710 µm sieve without residual lumps after gentle swirling for < 5 min.

The granule route has a distinct compliance footprint. If the intended product requires a delayed-release profile, the dried granules are coated in a Wurster insert with an aqueous methacrylic acid copolymer Type C dispersion at 15–20 % weight gain, plasticized with triethyl citrate at 10–20 % of polymer solids and talc at 30–50 % of polymer solids. Enteric-protected granules are tested by two-stage dissolution in USP 711: not more than 10 % release in 0.1 N HCl after 2 h, followed by not less than 80 % release in pH 6.8 phosphate buffer within 45 min. Water activity of the final granules is kept below 0.45 to prevent polymer film coalescence and to maintain taste-masking integrity. For oral suspension presentations, the reconstituted suspension is tested for deliverable dose per Ph. Eur. 2.9.27 or USP 698, and for microbial limits per Ph. Eur. 2.6.12 and 2.6.13. The main operational boundary is electrostatic agglomeration in the low-humidity granule bed; if the bed clumps, the atomization air is reduced and the inlet air dew point is raised to -5 °C to maintain controlled moisture without reintroducing aqueous binder.

When Lyophilized Injection Requires a Crystalline Bulking Agent

Injectable powder for the 9-37 peptide is manufactured as a lyophilized cake only after pre-formulation thermal analysis by modulated differential scanning calorimetry and freeze-dry microscopy establish the collapse temperature of the specific formulation. Because no compendial monograph provides a T g' value for this peptide sequence, each buffer system is characterized by freeze-dry microscopy at 0.1 °C/min; if collapse is observed below -30 °C, the formulation is rebalanced with a crystalline bulking agent and annealed. A starting lyophilization matrix contains 1–10 mg/mL peptide, 4–5 % w/v mannitol, 10–25 mM L-histidine or acetate buffer at pH 5.0–6.0, and 1–2 % w/v trehalose dihydrate where cryoprotection is needed. Mannitol is selected because it forms a crystalline scaffold during annealing at -20 °C to -15 °C for 2–4 h, reducing primary drying resistance and providing mechanical strength to the cake; however, uncontrolled mannitol crystallization can exclude buffer salts and produce a pH shift of 0.2–0.5 units upon reconstitution, so pH is re-measured after reconstitution with 0.9 % w/v sodium chloride or water for injection. The solution is compounded under nitrogen, adjusted to target pH, and filtered through a 0.22 µm PVDF membrane per ASTM F838-20 before filling into 2R or 6R Type I borosilicate vials at 0.5–1.0 mL or 1.0–2.0 mL fill volume. Stoppers are partially seated to allow vapour transport, and the vial load is frozen at -40 °C at 0.5–1 °C/min, held for 2 h, then annealed. Primary drying is run at shelf temperature -25 °C to -15 °C with chamber pressure 100–150 mTorr for 24–48 h, using product temperature thermocouples and comparative pressure measurement to detect endpoint. Secondary drying is conducted at 25–35 °C for 4–8 h to target residual moisture below 1.0 % by Karl Fischer USP 921 Method Ia. The terminal product is a white to off-white lyophilized cake for reconstitution to 10 mg/mL; reconstitution time should not exceed 3 min without visible particles.

The parenteral route has more restrictive compendial obligations than oral forms. The reconstituted solution is inspected for visible particulates per USP 790 and subvisible particles per USP 787 or Ph. Eur. 2.9.19, with per-container limits of 6000 particles ≤ 10 µm and 600 particles ≤ 25 µm for vials ≤ 100 mL. Sterility is demonstrated by membrane filtration per USP 71 or direct inoculation per Ph. Eur. 2.6.1, and bacterial endotoxins are tested per USP 85 with a limit not exceeding 5.0 EU/mg unless the clinical dose defines a lower limit. The critical process boundary is cake collapse: if the product temperature during primary drying approaches the T g' value, the cake shrinks and forms a glassy residue with high residual moisture and higher aggregation on reconstitution. If collapse is detected in freeze-dry microscopy at -30 °C, the mannitol concentration is increased from 4 % to 5 % w/v and the annealing time is extended to 4 h; if collapse persists, the fill volume is reduced from 1.0 mL to 0.7 mL to improve heat transfer. An incompatibility specific to mannitol-containing lyophilized formulations is the combination with phosphate buffer without controlled crystallization: phosphate can form a glass that lowers the collapse temperature and can concentrate and protonate peptide side chains during freezing. Therefore, histidine or acetate buffer is preferred unless the stability data demonstrate that phosphate is required.

Ready-to-Use Cartridge Chemistry and Terminal Sterilization Constraints

For ready-to-use cartridge presentation, liquid injection of the 9-37 peptide sequence is developed as a single-dose or multidose aqueous solution when the peptide remains monomeric and chemically stable at 2–8 °C for the projected shelf-life. Because the peptide contains ionizable residues, a pH-stability matrix is first generated by forced degradation at 5 °C, 25 °C, and 40 °C for up to 12 weeks in buffers ranging from pH 3.5 to 7.0. The starting formulation contains 1–10 mg/mL peptide, 10–25 mM acetate or histidine buffer, 0.7–0.9 % w/v sodium chloride or 4–5 % w/v mannitol for tonicity, and 0.02–0.05 % w/v polysorbate 80 only if surface adsorption to the cartridge glass is demonstrated. For multidose cartridges, phenol at 0.2–0.5 % w/v or m-cresol at 0.15–0.3 % w/v is added as an antimicrobial preservative, and preservative efficacy is tested per USP 51 or Ph. Eur. 5.1.3 with acceptance of not less than 1 log reduction for bacteria at 7 days. Osmolality is adjusted to 280–320 mOsm/kg by USP 785, and the solution is filtered through a 0.22 µm PES membrane with prefilter to remove aggregates; filter integrity is verified by bubble point or diffusive flow per ASTM F838-20. Filling is performed under aseptic conditions into 1.5 mL or 3 mL COC/COP polymer cartridges or Type I glass cartridges with FluroTec-coated plungers; terminal steam sterilization at 121 °C for 15 min is excluded because peptide degradation kinetics at basic pH and high temperature produce heterogeneous aggregates. The terminal product is a clear, colourless to pale yellow solution for subcutaneous or intravenous administration after dilution, with pH, osmolality, and visible particulate testing per USP 790 and Ph. Eur. 2.9.19 at release and on stability.

The liquid injection process is bounded by aggregation at low pH and oxidation at neutral pH. If the peptide has a methionine residue, the formulation is sparged with nitrogen during compounding and the headspace oxygen is kept below 2 % by volume; if peroxide-laden polysorbate 80 is required, it is added as a stabilizer only after peroxide content is measured below 5 µEq/mL, otherwise oxidation products above 0.5 % by HPLC increase. Metal contamination from the filling line is controlled by using 316L stainless steel with electropolished product-contact surfaces and by adding 0.1–0.5 mM disodium edetate only if transition-metal-catalyzed oxidation is confirmed by spiking studies with 10 ppb iron. The cartridge rubber components are tested for extractables and leachables per USP 1663 and 1664; silicone oil migration from prefilled syringe barrels can create subvisible droplets, so siliconized barrels are replaced with silicone-free polymer systems when the particle count fails USP 787. Terminal sterilization of the assembled cartridge is not performed; aseptic process simulation follows 21 CFR 211.67 and ISO 13408-2, with media fills accepted only at zero contaminated units for runs above 3000 units. The main incompatibility is with phosphate buffer under cold storage: phosphate salts can crystallize at 2–8 °C and cause pH drift above 0.3 units; histidine or acetate avoids this unless stability data justify otherwise.

Layering of the 9-37 peptide onto inert cores is used when a multiparticulate delivery system is required for dose-flexible oral administration or when the API cannot be compressed into a tablet without unacceptable degradation. In a Wurster fluid-bed coater, 710–850 µm sugar spheres or 500–710 µm microcrystalline cellulose spheres are charged, and a layering dispersion is prepared by dissolving or suspending the peptide with 3–5 wt% hypromellose E5 as binder in a 30–50 % v/v ethanol-water vehicle. The spray rate is set at 2–5 g/min per kilogram of cores, inlet air temperature at 35–45 °C, product temperature at 26–32 °C, and atomization air at 0.8–1.5 bar. The peptide load on the cores is built to 2–6 wt% of the final layered pellet mass, with a seal coat of hypromellose E5 at 2–4 % weight gain applied before any functional coat. If delayed release is required, a methacrylic acid copolymer Type C dispersion is applied at 15–20 % weight gain, plasticized with triethyl citrate at 10–20 % of polymer solids and talc at 30–50 % of polymer solids to reduce tack. After coating, the multiparticulates are cured at 40 °C for 2 h in a tray dryer, sieved through 1.0 mm and retained on 710 µm, and filled into hard capsules or sachets under ≤ 30 % RH. Two-stage dissolution testing per USP 711 is required for enteric-coated multiparticulates: not more than 10 % release in 0.1 N HCl after 2 h, followed by not less than 80 % release in pH 6.8 phosphate buffer within 45 min. The terminal product is a capsule or sachet containing 50–200 mg of coated multiparticulates, with each unit delivering the labelled peptide dose from a fixed number of pellets; the pellet count per unit is determined by assay and should not vary by more than ± 5 % RSD.

This multiparticulate process is limited by electrostatic adhesion of the layered peptide to the Wurster chamber walls when the inlet air dew point is below -10 °C; the condition is corrected by raising the dew point to 0–5 °C or by humidifying the chamber to 30–40 % RH without wetting the cores. If the layering dispersion causes core erosion, the spray rate is reduced or the ethanolic strength is increased to 50 % v/v to reduce water exposure. The enteric coating step introduces an additional incompatibility: residual water in the seal coat above 2.0 % causes polymer film cracking after curing; therefore, the seal-coated cores are dried to 1.5 % moisture by Karl Fischer before enteric coating. Published data for this specific sequence in enteric-coated multiparticulates is limited, so the coating weight gain is bracketed in a three-lot design from 10 % to 25 %, with acid uptake and dissolution profiles used to set the final range. If the peptide is acid-labile, the enteric coating is mandatory, and the acid-test release limit is tightened to < 5 % at 2 h; if the peptide is acid-stable, the functional coat is omitted and the multiparticulates are used for taste masking or prolonged release via an ethylcellulose barrier membrane at 3–8 % weight gain applied from an aqueous dispersion. The final capsules or sachets are tested for content uniformity per USP 905, moisture by USP 921 Method Ia, and dissolution by USP 711; stability storage follows ICH Q1A(R2) zones I–IV with the product protected at ≤ 25 °C and ≤ 30 % RH. The operational boundary for all coated multiparticulates is the mechanical integrity of the functional coat: if the coating cracks during compression into tablets, the dosage form must remain as a capsule or sachet; tableting of coated pellets is avoided unless 10 % or more of the tablet mass is placebo filler and compression force is below 8 kN.